Search results for: Multi-Indication Medicines

The US Inflation Reduction Act: What Do the Experts Think?

25 May 2023

…15 years to around 10. Companies may need to think more strategically about launch indications. Importantly, incentives for manufacturers to research and invest in new indication launches for existing therapies…

OHE Academy

…Payment Models for Multi-Indication Therapies Masterclass Free on-demand Masterclass Unlock the potential of multi-indication therapies at your own pace with our comprehensive on-demand Masterclass. Dive into the intersection of science,…

Medicine

…medicines is multifaceted, significantly influencing health outcomes and extending beyond healthcare, encompassing economic and societal dimensions. Medicines play a pivotal role in improving health outcomes, preventing illnesses, alleviating suffering, and…

OHE Presentations at HTAi: Tokyo 2016

24 May 2016

…can HTA’s in Asia respond to Increased Clinical Uncertainty: the potential for PBRSAs from Office of Health Economics   Making Value-Based Pricing a Reality – the Case for Multi-Indication Pricing by…

NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?

1 May 2024

…and prices for medicines. Beta-Interferon, a new treatment for Multiple Sclerosis (a disease that was poorly served by existing treatments), was the driver for taking the step. The evidence for…

Advancing Rare Disease Care: Challenges and Key Issues

28 February 2025

…(approved through the Innovative Medicines Fund). Of relevance to ultra-rare diseases in the UK, Highly Specialised Technologies (HST) guidance provides a route to appraisal and access for some orphan medicines,…

OHE at ISPOR Europe 2018

…medicines, and the approaches to address them. These challenges risk hindering the availability of life-changing treatments for children with rare diseases. Educational symposium: Indication-based Pricing; Who Wins, Who Loses, and…

International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective

1 May 2015

…different classes of medicines. In a majority of classes usage is below the two international averages. But while, for example, usage of cardiovascular medicines is low by international standards, use…

OHE at ISPOR Washington DC (1): HTA, Evidence and Pricing

9 June 2016

…this issue panel; please see his slides below. Adrian presented a European perspective on multi-indication drug including options from an OHE supported stakeholder forum. “Multi-indication Pricing: Do we want it?…